Avi Magid, Khetam Hussein, Halima Dabaja-Younis, Moran Szwarcwort-Cohen, Ronit Almog, Michal Mekel, Avi Weissman, Gila Hyams, Vardit Gepstein, Netanel A Horowitz, Hagar Cohen Saban, Jalal Tarabeia, Michael Halberthal, Yael Shachor-Meyouhas
{"title":"对第三次 BNT162b2 疫苗接种血清反应的了解可能会影响医护人员对加强剂量的依从性。","authors":"Avi Magid, Khetam Hussein, Halima Dabaja-Younis, Moran Szwarcwort-Cohen, Ronit Almog, Michal Mekel, Avi Weissman, Gila Hyams, Vardit Gepstein, Netanel A Horowitz, Hagar Cohen Saban, Jalal Tarabeia, Michael Halberthal, Yael Shachor-Meyouhas","doi":"10.3390/antib13030063","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Previous studies showed that the fourth SARS-CoV-2 vaccine dose has a protective effect against infection, as well as against severe disease and death. This study aimed to examine whether knowledge of a high-level antibody after the third dose may reduce compliance to the fourth booster dose among healthcare workers (HCWs).</p><p><strong>Methods: </strong>We conducted a prospective cohort study among HCWs vaccinated with the first three doses at Rambam Healthcare Campus, a tertiary hospital in northern Israel. Participants underwent a serological test before the fourth booster vaccine was offered to all of them, with results provided to participants. The population was divided into two groups, namely those with antibodies below 955 AU/mL and those with 955 AU/mL and higher, a cutoff found protective in a previous study. Multiple logistic regression was carried out to compare the compliance to the fourth booster between the two groups, adjusted for demographic and clinical variables.</p><p><strong>Results: </strong>After adjusting for the confounding variables, the compliance was higher in those with antibody levels below 955 AU/mL (OR = 1.41, <i>p</i> = 0.05, 95% CI 1.10-1.96). In addition, male sex and age of 60 years and above were also associated with higher vaccination rates (OR = 2.28, <i>p</i> < 0.001, 95% CI 1.64-3.17), (OR = 1.14, <i>p</i> = 0.043, 95% CI 1.06-1.75), respectively.</p><p><strong>Conclusions: </strong>Knowledge of the antibody status may affect compliance with the booster dose. Considering waning immunity over time, reduced compliance may affect the protection of HCWs who declined the fourth dose.</p>","PeriodicalId":8188,"journal":{"name":"Antibodies","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348218/pdf/","citationCount":"0","resultStr":"{\"title\":\"Knowledge of the Serological Response to the Third BNT162b2 Vaccination May Influence Compliance of Healthcare Workers to Booster Dose.\",\"authors\":\"Avi Magid, Khetam Hussein, Halima Dabaja-Younis, Moran Szwarcwort-Cohen, Ronit Almog, Michal Mekel, Avi Weissman, Gila Hyams, Vardit Gepstein, Netanel A Horowitz, Hagar Cohen Saban, Jalal Tarabeia, Michael Halberthal, Yael Shachor-Meyouhas\",\"doi\":\"10.3390/antib13030063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Previous studies showed that the fourth SARS-CoV-2 vaccine dose has a protective effect against infection, as well as against severe disease and death. This study aimed to examine whether knowledge of a high-level antibody after the third dose may reduce compliance to the fourth booster dose among healthcare workers (HCWs).</p><p><strong>Methods: </strong>We conducted a prospective cohort study among HCWs vaccinated with the first three doses at Rambam Healthcare Campus, a tertiary hospital in northern Israel. Participants underwent a serological test before the fourth booster vaccine was offered to all of them, with results provided to participants. The population was divided into two groups, namely those with antibodies below 955 AU/mL and those with 955 AU/mL and higher, a cutoff found protective in a previous study. Multiple logistic regression was carried out to compare the compliance to the fourth booster between the two groups, adjusted for demographic and clinical variables.</p><p><strong>Results: </strong>After adjusting for the confounding variables, the compliance was higher in those with antibody levels below 955 AU/mL (OR = 1.41, <i>p</i> = 0.05, 95% CI 1.10-1.96). In addition, male sex and age of 60 years and above were also associated with higher vaccination rates (OR = 2.28, <i>p</i> < 0.001, 95% CI 1.64-3.17), (OR = 1.14, <i>p</i> = 0.043, 95% CI 1.06-1.75), respectively.</p><p><strong>Conclusions: </strong>Knowledge of the antibody status may affect compliance with the booster dose. Considering waning immunity over time, reduced compliance may affect the protection of HCWs who declined the fourth dose.</p>\",\"PeriodicalId\":8188,\"journal\":{\"name\":\"Antibodies\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348218/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antibodies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/antib13030063\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/antib13030063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:以前的研究表明,第四剂SARS-CoV-2疫苗对感染、严重疾病和死亡有保护作用。本研究旨在探讨在接种第三剂疫苗后了解高水平抗体是否会降低医护人员对第四剂加强免疫的依从性:我们在以色列北部的一家三甲医院兰巴姆医疗中心对接种了前三剂疫苗的医护人员进行了一项前瞻性队列研究。在为所有参与者接种第四针加强疫苗之前,我们对他们进行了血清学检测,并向参与者提供了检测结果。人群被分为两组,即抗体低于 955 AU/mL 的人群和抗体高于 955 AU/mL 的人群。在对人口统计学和临床变量进行调整后,进行了多元逻辑回归,以比较两组患者对第四次加强治疗的依从性:结果:在调整了混杂变量后,抗体水平低于 955 AU/mL 的人群依从性更高(OR = 1.41,P = 0.05,95% CI 1.10-1.96)。此外,男性和 60 岁及以上年龄也分别与较高的疫苗接种率相关(OR = 2.28,p < 0.001,95% CI 1.64-3.17)和(OR = 1.14,p = 0.043,95% CI 1.06-1.75):对抗体状况的了解可能会影响对加强剂量的依从性。考虑到免疫力会随着时间的推移而减弱,依从性的降低可能会影响对拒绝接受第四剂的高危工人的保护。
Knowledge of the Serological Response to the Third BNT162b2 Vaccination May Influence Compliance of Healthcare Workers to Booster Dose.
Background: Previous studies showed that the fourth SARS-CoV-2 vaccine dose has a protective effect against infection, as well as against severe disease and death. This study aimed to examine whether knowledge of a high-level antibody after the third dose may reduce compliance to the fourth booster dose among healthcare workers (HCWs).
Methods: We conducted a prospective cohort study among HCWs vaccinated with the first three doses at Rambam Healthcare Campus, a tertiary hospital in northern Israel. Participants underwent a serological test before the fourth booster vaccine was offered to all of them, with results provided to participants. The population was divided into two groups, namely those with antibodies below 955 AU/mL and those with 955 AU/mL and higher, a cutoff found protective in a previous study. Multiple logistic regression was carried out to compare the compliance to the fourth booster between the two groups, adjusted for demographic and clinical variables.
Results: After adjusting for the confounding variables, the compliance was higher in those with antibody levels below 955 AU/mL (OR = 1.41, p = 0.05, 95% CI 1.10-1.96). In addition, male sex and age of 60 years and above were also associated with higher vaccination rates (OR = 2.28, p < 0.001, 95% CI 1.64-3.17), (OR = 1.14, p = 0.043, 95% CI 1.06-1.75), respectively.
Conclusions: Knowledge of the antibody status may affect compliance with the booster dose. Considering waning immunity over time, reduced compliance may affect the protection of HCWs who declined the fourth dose.
期刊介绍:
Antibodies (ISSN 2073-4468), an international, peer-reviewed open access journal which provides an advanced forum for studies related to antibodies and antigens. It publishes reviews, research articles, communications and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. Full experimental and/or methodical details must be provided. Electronic files or software regarding the full details of the calculation and experimental procedure - if unable to be published in a normal way - can be deposited as supplementary material. This journal covers all topics related to antibodies and antigens, topics of interest include (but are not limited to): antibody-producing cells (including B cells), antibody structure and function, antibody-antigen interactions, Fc receptors, antibody manufacturing antibody engineering, antibody therapy, immunoassays, antibody diagnosis, tissue antigens, exogenous antigens, endogenous antigens, autoantigens, monoclonal antibodies, natural antibodies, humoral immune responses, immunoregulatory molecules.